#Oxford Cannabinoid Technologies
#Oxford Cannabinoid Technologies · page 2
- Pharmaceutical
Oxford Cannabinoid Technologies Says Data From Pre-Clinical Study of Leading Drug Candidate Shows Positive Results
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce positive results from a pre-clinical pain study for its lead compound, OCT461201, targeting the global Chemotherapy Induced Peripheral Neuropathy (“CIPN”) treatment market valued at US$1.61bn in 2020 and forecasted…
- Pharmaceutical
EU Cannabis Stocks Review: Love Hemp jumps 60%, OCT sees recovery & more from Cellular Goods, Chill Brands and MGC Pharma
On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets.
- Pharmaceutical
Oxford Cannabinoid Technologies Welcomes Imperial Brands Director to Board and Appoints New Chair
Richard Guy Hathaway has been appointed to the Board as a Non-Executive Director, as a representative of Imperial Brands Ventures Limited (“Imperial”), with effect from 1 February 2022.
- Pharmaceutical
London Stock Exchange Cannabis Company Values Down Almost £200m From Early Peaks
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates for patients and investors alike.
- Pharmaceutical
High-Profile Director Quits Oxford Cannabinoid Technologies Board Following Chairman’s Recent Departure
Oxford Cannabinoid Technologies (OCT) has seen its second senior departure in under a month as it begins to recover from the fallout of a credit deal which breached market rules.
- Pharmaceutical
Oxford Cannabinoid Technologies Signs New Agreement With Stemtech
OCT believes Stemtech’s technology provides an in vitro translational model that will better predict results in humans.
- Pharmaceutical
Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach
THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules.
- Pharmaceutical
UK Cannabis Company’s C-Suite Left ‘Shaking Their Heads’ In Disbelief At Company’s Poor Stock Performance
FOLLOWING its listing on the London Stock Exchange in May this year Oxford Cannabinoid Technologies (OCT) has seen more than £20m wiped off its market capitalisation.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings New Partnerships Targeting Trigeminal Neuralgia
OXFORD Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (OCT), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the US$ multi-billion pain market, announces the signing of new partnerships to target trigeminal neuralgia (TN) – an increasingly prevalent chronic pain condition.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings Sign Exclusive Worldwide License Agreement With Canopy Growth
Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together, the “Group”), a company developing licensed prescription cannabinoid medicines for approval by regulatory agencies worldwide and targeting the U$ multi-billion pain market, is pleased to announce that on 21 September 2021 OCT signed an exclusive licensing agreement with Canopy…
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings Post IPO Review
OXFORD Cannabinoid Technologies Holdings plc (“OCTP” or the “Company”), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together the “Group”), a UK pharmaceutical company focussed on developing a portfolio of cannabinoid-based prescription medicines, approved by medicines regulatory agencies which target the pain market, is pleased to provide an update following its £16.5 million fundraise…
- Pharmaceutical
‘Patient Capital’ Backing LSE Debutant As It Eyes A Multi-Billion Pound Prize
LONDON Stock Exchange debutant Oxford Cannabinoid Technologies is aiming to emulate the success of GW Pharmaceuticals.
